



Year	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	Value Line Pub, Inc.	08-10
Sales per sh ^A	3.66	4.22	4.67	5.25	5.50	6.12	7.27	8.11	8.41	8.80	9.88	10.47	10.83	12.23	14.10	15.94	17.45	18.90	23.70	23.70
"Cash Flow" per sh	.56	.65	.73	.85	.93	1.06	1.26	1.46	1.62	1.83	2.03	2.27	2.46	2.85	3.36	3.84	4.20	4.65	6.05	6.05
Earnings per sh ^B	.41	.48	.55	.62	.69	.78	.93	1.09	1.21	1.34	1.49	1.70	1.91	2.23	2.70	3.10	3.45	3.80	4.95	4.95
Div's Decl'd per sh ^C	.14	.16	.19	.22	.25	.28	.32	.37	.43	.49	.55	.62	.70	.80	.92	1.10	1.28	1.44	1.84	1.84
Cap'l Spending per sh	.28	.31	.37	.42	.38	.36	.48	.52	.52	.54	.62	.59	.57	.71	.76	.73	.75	.75	.90	.90
Book Value per sh ^D	1.56	1.84	2.11	1.97	2.17	2.77	3.49	4.07	4.59	5.06	5.83	6.76	7.95	7.65	9.05	10.71	12.20	14.10	20.50	20.50
Common Shs Outst'g ^E	2664.4	2664.6	2665.3	2621.6	2571.9	2572.0	2590.7	2665.0	2690.3	2688.1	2779.4	2781.9	3047.2	2968.3	2968.0	2971.0	2940.0	2915.0	2800.0	2800.0
Avg Ann'l P/E Ratio	15.4	16.5	20.5	20.0	15.4	14.8	18.5	22.4	24.9	28.1	31.6	26.4	27.2	25.9	19.4	18.1	18.0	18.0	20.0	20.0
Relative P/E Ratio	1.17	1.23	1.31	1.21	.91	.97	1.24	1.40	1.44	1.46	1.80	1.72	1.39	1.41	1.11	.96	1.00	1.00	1.35	1.35
Avg Ann'l Div'd Yield	2.2%	2.1%	1.7%	1.8%	2.4%	2.4%	1.9%	1.5%	1.4%	1.3%	1.2%	1.4%	1.3%	1.4%	1.8%	2.0%	2.0%	2.0%	1.9%	1.9%

Category	202004	3Q2004	4Q2004	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Total Debt \$2,778 mill. Due in 5 Yrs \$700.0 mill.	627	601	662	1851	1467	1866	4261	1908	885												
LT Debt \$2,459 mill. LT Interest \$120.6 mill. (7% of Cap'l)	586	597	611	1851	1467	1866	4261	1908	885												
Leases, Uncapitalized Annual rentals \$144.0 mill.	1851	1467	1866	4261	1908	885															
Pension Assets-12/04 \$7,125 mill. Oblig. \$8,941 mill.	1851	1467	1866	4261	1908	885															
Pfd Stock None	1851	1467	1866	4261	1908	885															
Common Stock 2,973,544,570 shs. as of 5/1/05	1851	1467	1866	4261	1908	885															
MARKET CAP: \$201 billion (Large Cap)	1851	1467	1866	4261	1908	885															
CURRENT POSITION (SMILL.)	1851	1467	1866	4261	1908	885															
Cash Assets	9523	12884	13650	9523	12884	13650															
Receivables	6574	6831	7336	6574	6831	7336															
Inventory (FIFO)	3588	3744	3814	3588	3744	3814															
Other	3310	3861	3966	3310	3861	3966															
Current Assets	22995	27320	28766	22995	27320	28766															
Accts Payable	4996	5227	4038	4996	5227	4038															
Debt Due	1363	280	318	1363	280	318															
Other	7089	8420	8625	7089	8420	8625															
Current Liab.	13448	13927	12981	13448	13927	12981															

Business: Johnson & Johnson manufactures and sells health care products. Major lines by segment: Consumer (baby care, non-prescription drugs, sanitary protection, and skin care), Med. Device & Diag. (wound closures, minimally invasive surgical instruments, diagnostics, orthopedics, and contact lenses), and Pharmaceutical (contraceptives, psychiatric, anti-infective, and dermatological drugs). 2004 sales (operating income) by segment: Pharm., 47% (58%); Med. Device & Diag., 36% (31%); Consumer, 17% (11%). Int'l business, 41% of '04 sales; R&D, 11%. Has 109,900 empl.; 187,840 stockholders. Off/dir. own less than 1% (3/05 Proxy). Chrmn. & CEO: William Weldon. Inc.: NJ. Addr.: One J&J Plaza, New Brunswick, NJ 08933. Tel.: 732-524-0400. Web: www.jnj.com.

Johnson & Johnson's largest acquisition to date will probably close in about three months. Guidant stockholders approved the \$25 billion deal in late April. Permission is still required of U.S. and European regulators, but we think the merger will occur in the latter part of the September period. At that time, investors in Guidant will receive stock and cash worth \$76 for each of their shares. The acquirer will in turn get a lucrative and rapidly expanding cardiac rhythm management business. J&J will also get a bioerodable polymer and stents program, which should enhance its own long-term competitive stance in the nascent, highly profitable drug-eluting stents market. The purchase also eliminates a potential competitor that could have exerted substantial pricing and margin pressures in the stents arena. Modest earnings dilution is likely this year and next, but the addition should be accretive in the subsequent years. (Note: Guidant will be excluded from our figures until the merger actually closes.)

Fiscal Year Ends	Mar.Per	Jun.Per	Sep.Per	Dec.Per	Full Fiscal Year
2002	8743	9073	9079	9403	36298
2003	9831	10322	10455	11254	41862
2004	11559	11484	11553	12752	47348
2005	12832	12575	12500	13408	51315
2006	13750	13550	13400	14450	55150

Fiscal Year Ends	Mar.Per	Jun.Per	Sep.Per	Dec.Per	Full Fiscal Year
2002	.59	.60	.60	.44	2.23
2003	.69	.70	.69	.62	2.70
2004	.83	.82	.78	.67	3.10
2005	.97	.91	.86	.71	3.45
2006	1.02	1.01	.96	.81	3.80

Cal-endar	Mar.31	Jun.30	Sep.30	Dec.31	Full Year
2001	.16	.18	.18	.18	.70
2002	.18	.205	.205	.205	.80
2003	.20	.24	.24	.24	.92
2004	.24	.285	.285	.285	1.10
2005	.285	.33			

(A) Year ends on last Sunday of December. (B) Primary earnings through '96, diluted thereafter. Excludes nonrecurring gains/(losses): '90, 5c; '92, 23c; '98, 22c; '99, 2c; '01, (7c); '02, (7c); '03, Q2, (30c); '04, (26c) Next earnings report due mid-July. (C) Dividends historically paid mid: March, June, Sept., Dec. Div'd reinvestment plan available. (D) Incl. intang.: In '04, \$12.4 billion, \$4.17/sh. (E) In mill., adj. for stock splits.

To subscribe call 1-800-833-0046.

Company's Financial Strength	A++
Stock's Price Stability	100
Price Growth Persistence	90
Earnings Predictability	100